The Supreme Court Just Changed the Rules for Roundup Cancer Cases — But Your Story Is Not Over
If you are reading this at 2 a.m. because you used Roundup for years and then heard the word “non-Hodgkin lymphoma” from a doctor, you already know what fear sounds like. And if you just saw the news that the United States Supreme Court ruled against people like you — that federal law bars the lawsuits that won billions from Monsanto — you may feel like the last door just closed. It did not close all the way. But it changed, and we are not going to pretend it didn’t, because you deserve the truth from the first sentence.
Here is what actually happened, in plain English: on June 25, 2026, the Supreme Court ruled 7-2 that a federal pesticide law called FIFRA — the Federal Insecticide, Fungicide, and Rodenticide Act — preempts state-law claims that Monsanto failed to warn consumers about cancer risks on the Roundup label. The case started right here in St. Louis, Missouri, when a man who used Roundup for years in neighborhood beautification work sued Monsanto in state court after developing non-Hodgkin lymphoma. A Missouri jury awarded him $1.25 million in 2023. The Missouri Court of Appeals upheld that verdict in February 2025. The Supreme Court reversed it — and in doing so, effectively barred tens of thousands of similar failure-to-warn lawsuits across the country.
But the ruling is limited to failure-to-warn claims. The opinion says so. And that limitation is the crack in the wall that a carefully built case may still pass through — through design defect theory, through negligent testing, through fraud. Those theories are untested in the post-ruling landscape, they carry real risk, and they require a far more precise pleading than the failure-to-warn cases that came before. But they exist. And whether your case can use them depends on facts we need to see now, not later.
This page is for the person in St. Louis — or anywhere in Missouri, or anywhere in this country — who needs to understand what the ruling means for them, what evidence is still worth preserving, what the deadlines are, and whether there is still a path forward. We are Attorney911, The Manginello Law Firm. We handle toxic tort and product liability claims and catastrophic injury cases. We are writing this as the senior trial team that has spent decades inside this kind of fight — and we are going to tell you exactly what we see, including the parts that are hard to hear.
What the Supreme Court Actually Ruled on June 25, 2026
The decision in Durnell v. Monsanto came down to one question: does a federal pesticide labeling law override state courts that try to hold a manufacturer liable for not putting a cancer warning on its product — when the federal Environmental Protection Agency reviewed the science and chose not to require that warning?
The majority, in a 7-2 opinion written by Justice Kavanaugh, said yes. The reasoning had two steps. First, FIFRA’s express preemption provision prohibits states from imposing any labeling requirement “in addition to or different from” what the federal government has approved. A state-law failure-to-warn claim that would require Monsanto to add a cancer warning the EPA did not require is, by definition, a requirement “in addition to or different from” the federal label. Second, the majority reasoned that a cancer warning contradicting the EPA’s own conclusion that glyphosate is not likely carcinogenic to humans would constitute “misbranding” under FIFRA — because the label would contain information the federal agency considers inaccurate.
Justice Jackson, joined by Justice Gorsuch, dissented. She argued the majority misread the statute’s text and that a state-law claim tracking the federal prohibition on misbranded pesticides does not impose an additional or different requirement — it parallels the federal one. Her sharpest line was this:
The court’s majority ultimately made a ruling that “leaves Durnell without a remedy for the significant harms he has suffered.”
That sentence is not a lawyer’s technicality. It is a Supreme Court justice saying, in the public record, that a man who proved his case to a jury — who proved that Roundup caused his cancer and that Monsanto failed to warn him — now has no legal remedy at all under the theory that won. That is the reality we have to work with, and the reality we have to work past.
The St. Louis Case That Became the National Test
The case that reached the Supreme Court began in a Missouri state courtroom — specifically, in the City of St. Louis circuit court, a venue that has historically been regarded as a plaintiff-favorable forum for mass tort cases. The plaintiff was a St. Louis resident who used Roundup regularly over many years in neighborhood beautification efforts. He developed non-Hodgkin lymphoma, a cancer of the lymphatic system. He sued Monsanto in 2019, arguing the company failed to warn him of the cancer risk.
In 2023, a Missouri jury found that Monsanto had failed to warn of the danger and awarded $1.25 million in damages. In February 2025, the Missouri Court of Appeals for the Eastern District — headquartered right here in St. Louis — upheld the verdict. The appellate court found that Missouri’s warning requirements paralleled rather than conflicted with federal law, and that the EPA’s decision not to require a cancer warning did not absolve Monsanto of its separate obligation under Missouri law to warn consumers of known dangers.
The Supreme Court disagreed. It reversed the Missouri appellate court’s ruling, and in doing so, it overturned a verdict that a local jury and a local appeals court had already found to be sound. The practical effect: the $1.25 million award is gone, and the legal theory that produced it is no longer available — not just in Missouri, but nationwide.
This is where St. Louis becomes more than a location. The City of St. Louis circuit court has been a preferred forum for toxic tort plaintiffs because of favorable substantive law, procedural rules, and jury demographics that have historically shown a willingness to hold corporate defendants accountable. But the Supreme Court’s ruling is binding federal precedent that applies in every state courtroom in the country. No venue advantage — not St. Louis, not anywhere — can overcome a Supreme Court preemption holding. The local jury that heard the evidence and returned a verdict for the plaintiff did its job. The Supreme Court took that job away.
Why the Court Ruled the Way It Did: FIFRA Preemption Explained
FIFRA was originally passed in 1947 and substantially amended in 1972. It governs the registration, labeling, sale, and use of pesticides in the United States. The EPA administers it. Before any pesticide can be sold, the manufacturer must demonstrate that it will not cause “unreasonable adverse effects on the environment” — a phrase the statute defines to include effects on “water, air, land, and all plants and man and other animals.”
The preemption provision at the heart of the ruling prohibits states from imposing labeling requirements “in addition to or different from” those approved under federal law. This is express preemption — Congress wrote it directly into the statute. The question was never whether FIFRA preempts some state labeling requirements. It clearly does. The question was whether a state-law tort claim for failure to warn — where a jury holds a manufacturer liable for not putting a warning on the label — counts as a state “imposing” a labeling requirement.
The majority said it does. When a state court tells Monsanto it should have put a cancer warning on Roundup, and the EPA did not require one, the state court is effectively mandating a label “in addition to” the federally approved one. The majority went further: because the EPA has repeatedly concluded since 2009 that glyphosate is not likely carcinogenic to humans, a cancer warning would contradict the agency’s regulatory conclusion — making the product “misbranded” under FIFRA’s own terms.
The dissent read the same statute differently. Justice Jackson argued that a state-law claim that simply enforces the same obligation FIFRA already imposes — the duty not to misbrand a pesticide — does not add to or differ from federal law. It parallels it. Under this reading, a state court holding Monsanto liable for failing to warn is enforcing the federal prohibition on misleading labels, not creating a new requirement.
The majority rejected that framing. And because seven justices agreed with the majority, that rejection is now the law of the land.
Here is what a generalist lawyer misses about this ruling: the opinion is expressly limited to failure-to-warn claims. The word “warn” and the label are the entire battleground. A claim that does not depend on what the label says — that attacks the product’s design, the company’s testing decisions, or its representations to regulators — sits outside the preemption analysis the majority conducted. That distinction is the entire roadmap for what comes next, and a lawyer who files the same failure-to-warn complaint that worked in 2023 will get dismissed in 2026.
The Science That Drove a Decade of Lawsuits
The Roundup litigation was built on a scientific disagreement that is still unresolved. In 2015, the International Agency for Research on Cancer — a branch of the World Health Organization — classified glyphosate, the active ingredient in Roundup, as “probably carcinogenic to humans.” That classification was based on “limited” evidence of cancer in humans from real-world exposure and “sufficient” evidence of cancer in experimental animals. A 2025 study produced similar findings in laboratory rats.
The EPA has repeatedly reached the opposite conclusion. Since 2009, the agency has maintained that glyphosate is “not likely” to be carcinogenic to humans. It has allowed glyphosate-based weed killers to remain on the market without a cancer warning on the label. This regulatory position is what the Supreme Court’s majority relied on to find that a cancer warning would constitute “misbranding” — because it would contradict the EPA’s own conclusion.
The disagreement between IARC and the EPA is not a legal technicality. It is the scientific fault line running through every Roundup case. Plaintiffs’ experts point to the IARC classification, the animal studies, and mechanistic evidence showing how glyphosate may damage DNA and trigger cancerous changes in lymphocytes. The defense points to the EPA’s position, to other regulatory bodies that agree with the EPA, and to the absence of a consensus in the broader epidemiological literature.
What matters for your case is this: the Supreme Court did not resolve the scientific debate. It did not say glyphosate does not cause cancer. It did not say Monsanto was right. It said that even if glyphosate causes cancer, state courts cannot use failure-to-warn claims to punish Monsanto for not warning about it — because the federal labeling regime controls that decision, and the EPA decided no warning was needed. The science is still the science. The legal door for using it has narrowed, but it has not closed entirely.
What This Ruling Means for Pending and Future Cases
The immediate effect of Durnell is sweeping. Monsanto and its parent company, Bayer, had already paid out more than $10 billion to settle approximately 100,000 Roundup claims before the ruling. Those settlements are generally final — the ruling does not unwind resolved cases. But for the cases that were still pending when the decision came down, the landscape has fundamentally changed.
Cases premised solely on failure to warn — the theory that Monsanto should have put a cancer warning on the Roundup label — now face federal preemption dismissal in every jurisdiction. A motion to dismiss based on Durnell is likely to succeed in state and federal court alike. The Missouri courts that once allowed these claims to proceed must now dismiss them, because the Supreme Court’s ruling supersedes contrary state law nationwide.
The proposed $7.25 billion class action settlement — a framework designed to resolve remaining claims — may now face reexamination. If the primary liability theory that drove the settlement value has been preempted, the economics of the deal change for both sides. Whether that settlement survives, gets renegotiated, or collapses is an open question as of this writing.
Cases with viable alternative theories — and this is the critical category — may still proceed. The ruling’s stated limitation to failure-to-warn claims leaves room, at least in theory, for claims based on different legal theories. But “room in theory” is not the same as “a clear path to victory.” These alternative theories are untested in the post-Durnell landscape, and courts will scrutinize them closely to determine whether they are genuinely different from failure-to-warn or merely failure-to-warn dressed in different clothing.
The honest assessment: if your case is already filed on a failure-to-warn theory, it is in serious jeopardy. If you have not yet filed, the path forward requires a fundamentally different legal approach — one that begins with a careful evaluation of whether your specific facts support a theory the Supreme Court did not preempt.
The Legal Theories That May Still Survive After Durnell
The Supreme Court’s opinion is limited to failure-to-warn claims. That means a claim that does not require a labeling change — that does not depend on what the Roundup label said or did not say — may fall outside the preemption analysis. Three theories are the leading candidates, though none has been tested in the post-ruling landscape.
Design defect is the first. A design defect claim argues that the product itself — the glyphosate formulation — is unreasonably dangerous independent of whether the label warned adequately. The question is not “should Monsanto have warned?” but “should Monsanto have designed a safer product, or should it have sold this formulation at all?” This theory does not require a label change. It requires proving that the foreseeable risks of the glyphosate formulation outweigh its utility and that a reasonable alternative design existed. Whether this theory independently faces FIFRA preemption challenges is currently untested. A court could conclude that a design defect claim, if it effectively requires the manufacturer to reformulate or withdraw the product, also imposes a requirement “in addition to or different from” federal law. That question is open.
Negligent testing and research is the second. This theory alleges that Monsanto negligently conducted — or failed to conduct — adequate carcinogenicity testing before and after bringing Roundup to market. The claim is not that the label was wrong. It is that the company’s testing protocol was deficient, that it knew or should have known its testing was inadequate, and that proper testing would have revealed the cancer risk before people were exposed. The survivability of this theory depends on whether courts characterize it as imposing requirements “in addition to or different from” federal labeling standards, or as a standalone duty of reasonable care in research that exists independent of the label.
Fraud and misrepresentation is the third. This theory alleges that Monsanto knowingly misrepresented the safety of glyphosate to consumers, to regulators, or to the scientific community. It is not a labeling claim — it is a claim about affirmative misrepresentations that go beyond the label’s content. The overlap with EPA submission representations may create preemption complexities, and careful pleadings would need to be drafted to avoid the preempted warning framework. But if a plaintiff can show the company made knowing false statements about glyphosate’s safety — in marketing, in scientific publications, in communications that were not part of the label approval process — that theory may sit outside the preemption analysis.
Here is what the generalist misses: the line between a surviving theory and a preempted one is the line between “the label should have said X” and “the company did something wrong that had nothing to do with the label.” A complaint that spends three paragraphs on what Monsanto should have warned about will be dismissed as a repackaged failure-to-warn claim, even if it uses the words “design defect” in the caption. The pleading has to be built from the ground up to avoid the label entirely — to tell a story about corporate decision-making, testing, and representation that does not depend on what the bottle said.
The Company Behind Roundup: Monsanto and Bayer
Monsanto Company is the manufacturer of Roundup. It is now a wholly-owned subsidiary of Bayer AG, the German pharmaceutical and chemical conglomerate that acquired Monsanto in 2018. When you sue Monsanto today, you are suing a subsidiary of one of the largest chemical and pharmaceutical companies in the world.
The corporate structure matters for two reasons. First, it affects who pays. Monsanto is the named defendant in Roundup cases, but Bayer is the ultimate corporate parent with the deep balance sheet. Bayer has already demonstrated its willingness to resolve Roundup exposure — it paid more than $10 billion to settle approximately 100,000 claims. That settlement history tells you two things: the company has the resources to pay significant recoveries, and it has already shown a willingness to pay them when the legal pressure was sufficient.
Second, the corporate structure creates a discoverable web of internal documents. Monsanto’s pre-2015 internal safety studies, its post-IARC internal scientific assessments, its email communications, and its regulatory strategy documents are all potentially discoverable — if they have not been destroyed. The internal corporate knowledge of cancer risks, independent of label content, is exactly what alternative theories like design defect, negligent testing, and fraud need to survive. But these documents have a shelf life, and the longer you wait, the more likely they are to disappear through corporate restructuring, personnel turnover, and routine document-retention policies.
Bayer’s litigation strategy is now clear. They won the preemption fight at the Supreme Court, and they will deploy that victory aggressively. Every pending failure-to-warn case will face a motion to dismiss. Every new case filed on a failure-to-warn theory will be met with the same motion. The company will argue that Durnell bars the claim and that the case should be dismissed at the earliest possible stage. For cases with alternative theories, the company will argue that those theories are merely failure-to-warn in disguise and should be dismissed for the same reason.
The political environment currently favors Monsanto. In February 2026, the President signed an executive order calling glyphosate “crucial to the national security and defense” because of its role in food production. Congress is considering legislation that would prevent state and local governments from imposing stricter labeling requirements on pesticides than those approved by the EPA. Six states have introduced bills to limit pesticide manufacturers’ liability. A similar provision was stripped from the Farm Bill in April 2026, but the legislative push continues. Congressional Democrats have proposed legislation to override the Supreme Court’s ruling, but that effort is speculative given the current political landscape.
The Disease: Non-Hodgkin Lymphoma After Glyphosate Exposure
Non-Hodgkin lymphoma is a cancer that begins in the lymphatic system — the body’s network of lymph nodes, spleen, thymus, and bone marrow that produces and transports white blood cells called lymphocytes. When lymphocytes become abnormal, they can multiply uncontrollably, forming tumors in lymph nodes and other lymphatic tissue. There are many subtypes of non-Hodgkin lymphoma, classified by the type of lymphocyte affected (B-cell or T-cell) and the rate of growth (indolent or aggressive).
The diagnosis typically begins when a patient notices a swollen lymph node — in the neck, armpit, or groin — that does not go away. A biopsy confirms the diagnosis. Staging involves imaging (CT, PET scans) and sometimes bone marrow testing to determine how far the disease has spread. The treatment depends on the subtype and stage but may include chemotherapy regimens (such as R-CHOP), immunotherapy (such as rituximab), radiation therapy, and in some cases stem cell transplantation. Total medical costs frequently exceed several hundred thousand dollars, and ongoing surveillance for relapse continues for years — sometimes for life.
The proof problem in a Roundup case is specific causation — proving that this particular person’s non-Hodgkin lymphoma was caused by glyphosate exposure, not by something else. Non-Hodgkin lymphoma has multiple known risk factors: age, immune system suppression, certain infections, family history, and chemical exposures. The defense will argue that the plaintiff’s cancer was idiopathic — meaning it arose from unknown causes — or that it was caused by factors unrelated to Roundup. The plaintiff’s experts must establish both general causation (glyphosate can cause non-Hodgkin lymphoma in humans) and specific causation (this plaintiff’s exposure to glyphosate was sufficient to cause their particular cancer).
Specific causation is proven through a dose-response analysis: the expert reconstructs the plaintiff’s exposure history — how long they used Roundup, how frequently, what volume, what concentration, whether they used protective equipment — and compares that to the exposure levels associated with increased cancer risk in the scientific literature. This is why purchase receipts, product containers, and detailed exposure histories are so important. A plaintiff who can document years of regular, unprotected Roundup use has a far stronger specific-causation case than one who can only say “I used it sometimes.”
The family watching this disease unfold sees it in stages: the swollen node that wouldn’t go away, the biopsy, the staging scans, the port placed in the chest for chemotherapy, the fatigue and nausea of treatment, the watchful waiting after remission, the fear of every follow-up appointment. The medical record documents all of it — and that record, which is stable and retained per HIPAA requirements, is the foundation of both the injury proof and the damages proof.
What a Roundup Case Is Worth After the Ruling
We are going to give you the honest numbers, because the engine of trust is honesty — especially when honesty is hard.
Before the ruling, Roundup cases had significant value. The Hardeman verdict in California reached $80 million (including punitive components, though that case was built on the now-preempted failure-to-warn framework). The Durnell jury in St. Louis awarded $1.25 million. Monsanto paid more than $10 billion in aggregate to settle approximately 100,000 claims, implying an average per-claim resolution in the range of tens to hundreds of thousands of dollars. The proposed $7.25 billion class action settlement was designed to resolve remaining claims at varying individual values.
After the ruling, the calculus is fundamentally different. Cases premised solely on failure-to-warn now face likely dismissal — their value is effectively zero under that theory. The residual value exists only for cases with viable alternative theories (design defect, negligent testing, fraud) that survive preemption analysis. Those cases, if they survive, could still carry significant value — particularly where the plaintiff has strong exposure documentation, a clear NHL diagnosis, compelling internal corporate documents showing knowledge of cancer risks independent of the label, and a sympathetic personal story.
The realistic range for a post-Durnell case with viable alternative theories: potentially $0 (if the alternative theory is dismissed on preemption grounds) to $1-5 million (if the theory survives and the case proceeds to trial or meaningful settlement). But this range carries significant litigation risk and uncertainty. A plaintiff firm evaluating new Roundup exposure cases post-ruling would need to screen carefully for alternative-theory viability before accepting — and existing pending failure-to-warn cases face likely dismissal.
Punitive damages may remain theoretically available under non-failure-to-warn theories if reckless or intentional conduct in product design, testing, or corporate decision-making is proven — though the preemption landscape and the current political environment significantly constrain the practical recovery pathway.
Past results depend on the facts of each case and do not guarantee future outcomes. The $10 billion in settlements and the multi-million-dollar verdicts occurred under a legal framework that the Supreme Court has now dismantled for failure-to-warn claims. We will not pretend those results predict what your case will be worth today.
Evidence That Must Be Preserved — and How Fast It Can Disappear
Every piece of evidence in a toxic tort case has a clock on it. Some clocks are long. Some are brutally short. Knowing the difference is what saves a case.
Your medical records are stable. Hospital records, pathology reports, biopsy results, treatment histories, chemotherapy records, imaging studies, and follow-up notes are retained under HIPAA requirements and state medical-record retention rules. These documents establish your diagnosis, your treatment, your prognosis, and your damages. They are not going to disappear. But you should still request complete copies of your medical file — every page, every scan, every lab result — because having your own organized copy means your lawyer does not spend the first three months chasing records.
Roundup purchase receipts and product containers are perishable. Receipts fade, get thrown away, or are never kept in the first place. Product containers — the bottles, the concentrate jugs, the pump sprayers — get discarded, recycled, or stored in a shed where labels degrade and become illegible. Exposure witnesses — the people who saw you using Roundup, who can describe how often and how much — have memories that fade over time. The longer you wait to document your exposure history, the harder it becomes to reconstruct the dose-response relationship your specific-causation expert will need. Write down everything you can remember now: which products you used, what size containers, where you bought them, how often you applied them, what years, whether you wore gloves or a mask, whether you mixed concentrate or used ready-to-use formulations.
Internal Monsanto and Bayer corporate documents are critical and at high risk. Pre-2015 internal safety studies, post-IARC internal scientific assessments, email communications among scientists and executives, and regulatory strategy documents are the lifeblood of alternative theories. They show what the company knew about cancer risks and when — independent of what the label said. But corporate document-retention policies, restructuring, personnel turnover, and Bayer’s ongoing integration of Monsanto’s operations may eliminate access to these documents over time. Litigation holds — formal demands that a company preserve specific documents — must be served promptly on all potentially relevant custodians. In a mass tort context, some of these documents may already be available through discovery in prior settled cases, but access depends on protective orders and settlement confidentiality terms.
EPA registration files and label approval correspondence are stable. Federal regulatory records are archived under federal recordkeeping requirements. These files show what Monsanto told the EPA, what the EPA reviewed, and whether Monsanto ever petitioned the agency to add a cancer warning. This is directly relevant to the company’s “we could not have warned without EPA approval” argument — and to alternative-theory framing that separates the company’s regulatory conduct from its labeling obligations.
Published scientific literature is permanent. The 2015 IARC monograph, the 2025 rat study, the EPA’s assessments, and the broader peer-reviewed literature on glyphosate carcinogenicity are all published and archived. They are the foundation for general-causation expert testimony and are not at risk of disappearing.
The fastest-dying evidence is the exposure evidence — the receipts, the containers, the witness memories. That is where urgency lives. The most strategically important evidence for alternative theories is the internal corporate documentation — and that requires litigation holds that only a lawyer can send.
The Defense Playbook: What Monsanto’s Lawyers Will Do
Monsanto and Bayer have one of the most sophisticated litigation defense operations in the world. They have already fought tens of thousands of Roundup cases. They know every play. Here is what they will run, and here is the counter to each.
Play 1: The preemption motion to dismiss. This is now their strongest weapon. They will file a motion to dismiss at the earliest stage of the case, arguing that Durnell bars any claim related to Roundup and cancer warnings. The counter: the complaint must be drafted from the outset to assert theories that are genuinely independent of the label — design defect, negligent testing, fraud. If the complaint mentions warnings, labeling, or what Monsanto should have told consumers, the motion to dismiss will likely succeed. The pleading is everything.
Play 2: The “EPA said it’s safe” defense. Monsanto will point to the EPA’s repeated conclusions that glyphosate is not likely carcinogenic to humans. They will argue that the federal regulatory authority has spoken and that state courts cannot second-guess it. The counter: the EPA’s regulatory conclusion does not resolve the scientific question — IARC reached the opposite conclusion, the 2025 rat study supports IARC, and a jury is entitled to hear the scientific disagreement. But after Durnell, this argument works only for theories that do not depend on the label. For failure-to-warn, the EPA’s conclusion is now legally dispositive on the preemption question.
Play 3: Specific causation attack. Monsanto’s experts will argue that the plaintiff’s non-Hodgkin lymphoma was caused by something else — age, genetics, immune conditions, other chemical exposures, or idiopathic factors. They will challenge the plaintiff’s dose reconstruction as speculative. The counter: meticulous exposure documentation (receipts, containers, witness statements, usage logs), board-certified hematologist-oncologists and toxicologists with glyphosate-specific research credentials, and epidemiologists who can establish general and specific causation through mechanisms not dependent on label adequacy. The exposure history is the foundation — without it, no expert can opine on specific causation with confidence.
Play 4: The “we couldn’t have warned” argument. Monsanto will argue that even if it wanted to add a cancer warning, EPA regulations prohibit manufacturers from changing safety warnings without the agency’s prior approval — and Monsanto never asked the EPA for permission to add one. The counter for alternative theories: this argument only matters for failure-to-warn claims, which are already preempted. For design defect, negligent testing, or fraud, what Monsanto could or could not have put on the label is irrelevant — the question is whether the company’s product design, testing, or representations were independently unreasonable.
Play 5: Settlement leverage erosion. With the preemption ruling in hand, Monsanto’s settlement leverage has increased dramatically. They will offer less — or nothing — for cases they believe will be dismissed on preemption grounds. The counter: identify cases where strong alternative-theory facts, deep corporate document caches, or sympathetic plaintiffs still create meaningful settlement incentives — and be honest with the client about the changed settlement landscape.
Missouri Law: Your Deadline and Your Rights
Missouri law governs the underlying Durnell case, and it governs any new Roundup case filed in Missouri state courts. Here is what you need to know.
Missouri’s statute of limitations for personal injury actions is five years. This means you generally have five years from the date you knew or should have known that your injury was caused by Roundup to file a lawsuit. In toxic tort cases, this clock usually starts when you receive your cancer diagnosis and learn — or should have learned — that your exposure to glyphosate may have caused it. This is called the discovery rule, and it is critical in toxic tort cases because the disease often appears years or decades after the exposure.
If the plaintiff has died, Missouri’s wrongful death statute of limitations is three years from the date of death. A survival action — which carries the claim the decedent would have had for pain, suffering, and economic loss between injury and death — follows the same limitations period as the underlying personal injury claim. Families who lost a loved one to non-Hodgkin lymphoma after Roundup exposure should understand both deadlines. If you are considering a wrongful death claim, the three-year clock is shorter and less forgiving than the personal injury deadline.
Missouri follows pure comparative fault. This means your recovery is reduced by your percentage of fault, but it is never barred entirely — even if you were 99% at fault, you could still recover 1% of your damages. In the Roundup context, the defense may argue that you assumed the risk by using a chemical pesticide without protective equipment, or that your own negligence contributed to your exposure. Missouri’s pure comparative fault rule means these arguments reduce your recovery but do not eliminate it.
The Missouri Court of Appeals for the Eastern District, headquartered in St. Louis, had upheld the Durnell verdict before the Supreme Court reversed it. The Missouri courts are familiar with Roundup litigation. The City of St. Louis circuit court has been a preferred forum for these cases. But no Missouri court — no state court anywhere — can override a Supreme Court preemption ruling. The local advantage that St. Louis once offered for failure-to-warn claims has been neutralized by Durnell. What remains is a Missouri jury pool that has historically been willing to hold corporate defendants accountable — which still matters if your alternative-theory case survives to trial.
The current political environment in Missouri and nationally is relevant. The presidential executive order calling glyphosate “crucial to national security” and proposed federal legislation to further shield pesticide manufacturers create a headwind for these cases. Congressional override legislation has been proposed but is speculative. The legal landscape could shift — in either direction — depending on future elections, regulatory changes, and legislative action. But you cannot count on a future legal change to save a case you failed to file on time.
What to Do in the First 72 Hours
If you used Roundup and developed non-Hodgkin lymphoma — or if someone you love did and they are no longer here — the steps you take in the first days matter. Here is the roadmap.
First, get your medical records organized. Request complete copies of every relevant medical record: the pathology report that confirmed your non-Hodgkin lymphoma diagnosis, your treatment history (chemotherapy, immunotherapy, radiation, stem cell transplant), your imaging studies, your follow-up notes, your prognosis. These records are stable — they will not disappear — but having your own organized copy saves weeks of preparation time once a lawyer evaluates your case.
Second, document your exposure history in writing. Right now, while your memory is freshest, write down everything you can remember about your Roundup use: which products (Roundup concentrate, Roundup ready-to-use, Roundup Extended Control), what size containers, where you bought them (Home Depot, Lowe’s, local hardware store, farm supply), how often you used them (weekly, monthly, seasonally), what years (start and end dates), how you applied them (pump sprayer, hose-end sprayer, backpack sprayer), whether you wore gloves, a mask, or long sleeves, whether you mixed concentrate yourself, whether you ever got the product on your skin or breathed the spray. Photograph any product containers you still have, including the label and any lot numbers. Find and preserve any purchase receipts — credit card statements, store receipts, online order confirmations.
Third, identify your exposure witnesses. Who saw you using Roundup? A spouse, a neighbor, a coworker, a landscaping client? Write down their names and contact information. Their memories will fade. Their statements, captured now, can establish the duration, frequency, and volume of your exposure — the foundation of your specific-causation case.
Fourth, do not sign anything from Monsanto, Bayer, or any claims administrator. If you receive a letter, a settlement offer, or a release form from any entity related to Roundup litigation, do not sign it. Do not return it. Do not call the number on it. Bring it to a lawyer. The proposed $7.25 billion class action settlement may be reexamined in light of the Supreme Court ruling, and you should not agree to anything until you understand whether your case has value outside the failure-to-warn framework.
Fifth, do not give a recorded statement to any insurance adjuster, claims representative, or investigator. If someone calls you and says they “just want to ask a few questions,” that call is designed to lock you into a narrative that helps the defense. Decline. Say nothing. Call a lawyer.
Sixth, call a lawyer. Not next month. Not after you “feel better.” The statute of limitations is running regardless of the changing legal landscape, and the evidence that alternative theories need — particularly your exposure documentation and your witnesses’ memories — degrades with every passing day. A free consultation costs nothing and commits you to nothing. It simply gives you the information you need to make a decision.
Frequently Asked Questions
Can I still sue Monsanto if I got cancer from Roundup?
The failure-to-warn theory that produced the large verdicts and the $10 billion in settlements has been preempted by the Supreme Court’s ruling. But the ruling is expressly limited to failure-to-warn claims. Alternative legal theories — design defect, negligent testing, and fraud — may still be available depending on the specific facts of your exposure history, your diagnosis timeline, and the product formulations you used. These theories are untested in the post-ruling landscape and carry significant litigation risk, but they are not preempted on their face. Your case must be evaluated individually by a lawyer who understands the difference between a preempted claim and a potentially surviving one.
My Roundup lawsuit is already filed — what happens to my case?
If your case was filed on a failure-to-warn theory, it faces a likely motion to dismiss based on the Supreme Court’s ruling in Durnell. Monsanto’s lawyers will file this motion in every pending failure-to-warn case. Your attorney should be evaluating whether your complaint can be amended to assert alternative theories that fall outside the preemption analysis. Whether amendment is possible depends on the specific facts alleged, the evidence available, and the procedural posture of your case. If your case is in active litigation, your attorney should be preparing for the preemption challenge now — not waiting for it to arrive.
What is FIFRA preemption and why did the Supreme Court say it bars my claim?
FIFRA is the federal law that governs pesticide labeling. It contains an express preemption provision that prohibits states from imposing labeling requirements “in addition to or different from” those approved under federal law. The Supreme Court held that a state-law failure-to-warn claim — which requires a jury to find that Monsanto should have put a cancer warning on the Roundup label — is a state-imposed labeling requirement “in addition to” the federally approved label, because the EPA reviewed the science and chose not to require a cancer warning. The majority also reasoned that a cancer warning contradicting the EPA’s conclusion would constitute “misbranding” under FIFRA. The dissent argued the state claim paralleled rather than contradicted federal law, but the majority’s view controls.
If failure-to-warn is preempted, what other legal theories might work?
Three theories are the leading candidates. Design defect argues the glyphosate formulation itself is unreasonably dangerous, independent of the label. Negligent testing argues Monsanto failed to conduct adequate carcinogenicity testing. Fraud and misrepresentation argues the company knowingly misrepresented glyphosate’s safety to consumers or regulators. None of these theories has been tested in the post-Durnell landscape, and all face potential preemption challenges of their own. The key distinction is whether the theory depends on what the label said — if it does, it is likely preempted. If it attacks corporate conduct independent of the label, it may survive. What happens if you lose your case is a real question in this landscape — and the honest answer is that these theories carry genuine risk.
How long do I have to file a Roundup cancer lawsuit in Missouri?
Missouri’s statute of limitations for personal injury actions is five years. In toxic tort cases, the clock generally starts when you discovered — or reasonably should have discovered — that your injury was caused by the exposure. For most Roundup plaintiffs, this means the clock starts around the date of your non-Hodgkin lymphoma diagnosis, particularly if you learned around that time that glyphosate may cause cancer. If the plaintiff has died, Missouri’s wrongful death statute of limitations is three years from the date of death. These deadlines continue running regardless of the changing legal landscape — Congress could pass an override law tomorrow, and your statute of limitations would still be expiring on its original schedule.
I already settled my Roundup case — does this ruling affect me?
Generally, no. Settlements that have been finalized and paid are final. The Supreme Court’s ruling does not unwind resolved cases or reopen settled claims. If you signed a release and received payment, your case is over. If you are enrolled in the proposed $7.25 billion class action settlement but your claim has not been finally resolved, the settlement may face reexamination in light of the ruling, and you should consult with a lawyer about your options.
What is the status of the $7.25 billion class action settlement?
The proposed class action settlement was designed to resolve remaining Roundup claims, but its framework was built on the failure-to-warn theory that the Supreme Court has now preempted. The settlement may be reexamined, renegotiated, or restructured in light of the ruling. If you are a class member or a potential class member, you should not assume the settlement will proceed on its original terms. Monitor developments carefully and consult with a lawyer about whether opting out of a class settlement and pursuing an individual alternative-theory case may be more advantageous for your specific facts.
If Congress passes a law to override the ruling, will my case be revived?
Some members of Congress have proposed legislation to override the Supreme Court’s ruling, but that effort is speculative given the current political environment — which includes a presidential executive order designating glyphosate as “crucial to national security” and proposed legislation to further shield pesticide manufacturers from liability. Congressional action could theoretically restore the failure-to-warn vehicle, but you cannot rely on a hypothetical future statute to save a case you failed to file on time. The statute of limitations runs regardless. If you have a potential claim, the safest course is to evaluate it now under the current legal landscape and file within the existing deadline.
Does the Supreme Court ruling apply to pesticides other than Roundup?
The ruling in Durnell was specifically about Roundup and glyphosate, but the legal principle — that FIFRA preempts state failure-to-warn claims when the EPA has reviewed and declined to require a specific warning — applies to all pesticides regulated under FIFRA. This means the ruling will likely be cited by other pesticide manufacturers facing similar failure-to-warn claims. The broader principle at stake is whether Congress or federal agencies can block states from protecting people when federal regulators have not required companies to warn the public about potential harm.
What evidence do I need to preserve if I’m considering a Roundup case?
Your medical records (diagnosis, pathology, treatment, prognosis) are the foundation and are stable. Your exposure evidence — purchase receipts, product containers with labels, detailed usage history, and witness statements — is perishable and must be documented immediately. If you have any physical Roundup containers, photograph them from every angle, including the label and any lot numbers, and store them safely. Write down your complete exposure history while your memory is fresh. Identify anyone who witnessed your Roundup use. Do not discard anything that shows you purchased or used Roundup. And do not sign any release or give any recorded statement to any claims administrator, insurance adjuster, or investigator without consulting a lawyer first.
Why Attorney911
We are Attorney911 — The Manginello Law Firm, PLLC. We are based in Houston, Texas, and we take catastrophic injury and toxic tort cases across the country, including in Missouri, working with local counsel where required. We are writing this page not because we have all the answers to a ruling that just changed the legal landscape three days ago — no one does — but because we know how to ask the right questions, find the right experts, and build the right case for the world that exists now, not the one that existed before June 25, 2026.
Ralph Manginello, our managing partner, has spent 27+ years in courtrooms, including federal court. He was a journalist before he was a lawyer — which means he reads a Supreme Court opinion the way a reporter reads a story, looking for what the words actually do, not just what they seem to say. The Durnell opinion is 7-2, but the majority’s own limitation to failure-to-warn claims is the sentence that matters, and Ralph reads every sentence.
Lupe Peña, our associate attorney, spent years inside a national insurance-defense firm before he joined our side of the table. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims — and now he uses that knowledge for injured clients. He knows how a company like Monsanto values a claim from the inside, and he knows where the pressure points are when the legal landscape has shifted in the defendant’s favor. Lupe is fluent in Spanish and conducts full client consultations in Spanish without an interpreter.
We work on contingency. That means we do not get paid unless we win your case. The fee is 33.33% before trial and 40% if the case goes to trial. Your first consultation is free, and it is confidential. We have a 24/7 live staff — not an answering service — because the moment you decide to call is rarely during business hours. Hablamos Español.
We are not going to tell you your case is easy. It is not. The Supreme Court has dealt Roundup plaintiffs a severe blow, and the political environment is currently hostile to these claims. But we are also not going to tell you your case is hopeless, because the ruling’s own limitation to failure-to-warn claims leaves a door — narrow, untested, and requiring precise legal craftsmanship — that the right case, built the right way, may still walk through.
What we will do is evaluate your case honestly. If we are not the right fit — if your case does not support an alternative theory, or if the legal landscape makes your claim unviable — we will tell you. If we believe there is a path forward, we will walk it with you, and we will build the case from the ground up to fit the world as it is now, not as it was before the ruling changed everything.
The call is free. The consultation is confidential. The number is 1-888-ATTY-911 (1-888-288-9911). You can also reach us at our contact page.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Nothing here creates an attorney-client relationship. But everything here is written by lawyers who know this fight — and who know that the worst thing you can do, after a ruling like this, is nothing.